Trial Profile
Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS Doses of 180 ug or 270 ug in Combination With Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater Than 85 kg
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 02 Jun 2010 New source identified and integrated (Roche record.)
- 23 Feb 2010 Actual initiation date (Jan 2004) added as reported by Roche record.
- 20 Apr 2006 Status changed from in progress to completed.